SOUTH SAN FRANCISCO, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA) a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced the upcoming presentation of five preclinical abstracts, highlighting the potential of CB-839, the Company’s novel, orally bioavailable glutaminase inhibitor, at the American Association for Cancer Research, taking place April 18-22, 2015 in Philadelphia, Pennsylvania. Details for the two oral presentations and three poster presentations are as follows:
Oral Presentations:
| Evaluation of the glutaminase inhibitor CB-839 in non-small cell lung cancer |
| Abstract #4710 |
| Presenter: Lindsey Boroughs, Laboratory of Ralph Debaradinis, UT Southwestern |
| Minisymposium: Metabolism and Cancer 3 |
| Tuesday, April 21, 2015 at 3:35pm-3:50pm EDT |
| Pennsylvania Convention Center, Room 201 |
| CB-839, a selective glutaminase inhibitor, synergizes with signal transduction pathway inhibitors to enhance anti-tumor activity |
| Abstract #4711 |
| Presenter: Frank Parlati, Calithera Biosciences |
| Minisymposium: Metabolism and Cancer 3 |
| Tuesday, April 21, 2015 at 3:50pm-4:05pm EDT |
| Pennsylvania Convention Center, Room 201 |
Poster Presentations:
| Glutaminase inhibitors suppress pyrimidine synthesis and promote DNA replication stress in VHL-deficient human renal cancer cells |
| Abstract #1123 |
| Presenter: Arimichi Okazaki, Laboratory of Othon Iliopoulus, Massachusetts General Hospital |
| Poster Section 6, Board 1 |
| Monday, April 20, 2015 at 8:00am-12:00pm EDT |
| CB839, an orally bioavailable glutaminase inhibitor, shows potent antitumor activity in vitro against models of soft tissue sarcoma and chondrosarcoma |
| Abstract #4450 |
| Presenter: Tahir Sheikh, Laboratory of Gary Schwartz, Columbia University |
| Poster Section 30, Board 7 |
| Tuesday, April 21, 2015 at 1:00pm-5:00pm EDT |
| A new anticancer strategy based on inhibiting mitochondrial proline dehydrogenase (PRODH) and exploiting synthetic lethal interactions with p53 restoration and/or glutaminase (GLS1) inhibition |
| Abstract #5402 |
| Presenter: Gary Scott, Laboratory of Christopher Benz, Buck Institute |
| Poster Section 30, Board 14 |
| Wednesday, April 22, 2015 at 8:00am-12:00pm EDT |
The meeting abstracts can be viewed online through the AACR website at www.aacr.org.
About Calithera Biosciences
Calithera Biosciences is a clinical-stage company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology. Calithera’s lead clinical candidate, CB-839, is a first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism, and is currently being tested in patients with solid and hematological cancers. Calithera Biosciences is headquartered in South San Francisco. For more information about Calithera Biosciences, please visit www.calithera.com.
CONTACT: Jennifer McNealey ir@Calithera.com 650-870-1071
Help employers find you! Check out all the jobs and post your resume.
